Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21ClN4O4S |
| Molecular Weight | 436.912 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)COC1=NC=C(C=C1Cl)N2N=C(C)C3=C2C=CC(=C3)C(=O)NS(C)(=O)=O
InChI
InChIKey=RVTSXVZXEGFIPW-UHFFFAOYSA-N
InChI=1S/C19H21ClN4O4S/c1-11(2)10-28-19-16(20)8-14(9-21-19)24-17-6-5-13(7-15(17)12(3)22-24)18(25)23-29(4,26)27/h5-9,11H,10H2,1-4H3,(H,23,25)
PF-05241328 is a novel, potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7). It was developed for the pain treatment. It is highly plasma protein bound. PF-05241328 was ruled out based on half-life as the peak to trough ratios for this compound on twice-daily administration would require high therapeutic indices.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8RAL5N48VT
Created by
admin on Tue Apr 01 18:17:20 GMT 2025 , Edited by admin on Tue Apr 01 18:17:20 GMT 2025
|
PRIMARY | |||
|
68109743
Created by
admin on Tue Apr 01 18:17:20 GMT 2025 , Edited by admin on Tue Apr 01 18:17:20 GMT 2025
|
PRIMARY | |||
|
DB15124
Created by
admin on Tue Apr 01 18:17:20 GMT 2025 , Edited by admin on Tue Apr 01 18:17:20 GMT 2025
|
PRIMARY | |||
|
1387633-03-5
Created by
admin on Tue Apr 01 18:17:20 GMT 2025 , Edited by admin on Tue Apr 01 18:17:20 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
